Spike mutation D614G alters SARS-CoV-2 fitness - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. Skip to main page content An official website of the United States government Here's how you know The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. Log in Show account info Close Account Logged in as: username Dashboard Publications Account settings Log out Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search: Search Advanced Clipboard User Guide Save Email Send to Clipboard My Bibliography Collections Citation manager Display options Display options Format Abstract PubMed PMID Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel Email citation Email address has not been verified. Go to My NCBI account settings to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel Add to Collections Create a new collection Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Please try again Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Please try again Add Cancel Your saved search Name of saved search: Search terms: Test search terms Would you like email updates of new search results? Saved Search Alert Radio Buttons Yes No Email: (change) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy Full text links Nature Publishing Group Free PMC article Full text links Actions Cite Collections Add to Collections Create a new collection Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Please try again Add Cancel Permalink Permalink Copy Display options Display options Format AbstractPubMedPMID Page navigation Title & authors Erratum in Abstract Conflict of interest statement Figures Update of Comment in References Publication types MeSH terms Substances Grants and funding LinkOut - more resources Title & authors Erratum in Abstract Conflict of interest statement Figures Update of Comment in References Publication types MeSH terms Substances Grants and funding LinkOut - more resources Nature Actions Search in PubMed Search in NLM Catalog Add to Search . 2021 Apr;592(7852):116-121. doi: 10.1038/s41586-020-2895-3. Epub 2020 Oct 26. Spike mutation D614G alters SARS-CoV-2 fitness Jessica A Plante #  1   2   3 , Yang Liu #  4 , Jianying Liu #  2   3 , Hongjie Xia  4 , Bryan A Johnson  2 , Kumari G Lokugamage  3 , Xianwen Zhang  4 , Antonio E Muruato  2   3 , Jing Zou  4 , Camila R Fontes-Garfias  4 , Divya Mirchandani  1   2   3 , Dionna Scharton  1   2   3 , John P Bilello  5 , Zhiqiang Ku  6 , Zhiqiang An  6 , Birte Kalveram  7 , Alexander N Freiberg  2   7   8   9 , Vineet D Menachery  2   3 , Xuping Xie  10 , Kenneth S Plante  11   12   13 , Scott C Weaver  14   15   16   17   18   19   20 , Pei-Yong Shi  21   22   23   24   25   26 Affiliations Expand Affiliations 1 World Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, TX, USA. 2 Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA. 3 Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA. 4 Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA. 5 Gilead Sciences, Foster City, CA, USA. 6 Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA. 7 Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA. 8 Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX, USA. 9 Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA. 10 Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA. xuxie@utmb.edu. 11 World Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, TX, USA. ksplante@utmb.edu. 12 Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA. ksplante@utmb.edu. 13 Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA. ksplante@utmb.edu. 14 World Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, TX, USA. sweaver@utmb.edu. 15 Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA. sweaver@utmb.edu. 16 Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA. sweaver@utmb.edu. 17 Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX, USA. sweaver@utmb.edu. 18 Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA. sweaver@utmb.edu. 19 Institute for Translational Sciences, University of Texas Medical Branch, Galveston, TX, USA. sweaver@utmb.edu. 20 Sealy Center for Structural Biology and Molecular Biophysics, University of Texas Medical Branch, Galveston, TX, USA. sweaver@utmb.edu. 21 Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA. peshi@utmb.edu. 22 Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA. peshi@utmb.edu. 23 Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX, USA. peshi@utmb.edu. 24 Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA. peshi@utmb.edu. 25 Institute for Translational Sciences, University of Texas Medical Branch, Galveston, TX, USA. peshi@utmb.edu. 26 Sealy Center for Structural Biology and Molecular Biophysics, University of Texas Medical Branch, Galveston, TX, USA. peshi@utmb.edu. # Contributed equally. PMID: 33106671 PMCID: PMC8158177 DOI: 10.1038/s41586-020-2895-3 Item in Clipboard Spike mutation D614G alters SARS-CoV-2 fitness Jessica A Plante et al. Nature. 2021 Apr. Show details Display options Display options Format Abstract PubMed PMID Nature Actions Search in PubMed Search in NLM Catalog Add to Search . 2021 Apr;592(7852):116-121. doi: 10.1038/s41586-020-2895-3. Epub 2020 Oct 26. Authors Jessica A Plante #  1   2   3 , Yang Liu #  4 , Jianying Liu #  2   3 , Hongjie Xia  4 , Bryan A Johnson  2 , Kumari G Lokugamage  3 , Xianwen Zhang  4 , Antonio E Muruato  2   3 , Jing Zou  4 , Camila R Fontes-Garfias  4 , Divya Mirchandani  1   2   3 , Dionna Scharton  1   2   3 , John P Bilello  5 , Zhiqiang Ku  6 , Zhiqiang An  6 , Birte Kalveram  7 , Alexander N Freiberg  2   7   8   9 , Vineet D Menachery  2   3 , Xuping Xie  10 , Kenneth S Plante  11   12   13 , Scott C Weaver  14   15   16   17   18   19   20 , Pei-Yong Shi  21   22   23   24   25   26 Affiliations 1 World Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, TX, USA. 2 Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA. 3 Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA. 4 Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA. 5 Gilead Sciences, Foster City, CA, USA. 6 Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA. 7 Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA. 8 Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX, USA. 9 Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA. 10 Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA. xuxie@utmb.edu. 11 World Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, TX, USA. ksplante@utmb.edu. 12 Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA. ksplante@utmb.edu. 13 Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA. ksplante@utmb.edu. 14 World Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, TX, USA. sweaver@utmb.edu. 15 Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA. sweaver@utmb.edu. 16 Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA. sweaver@utmb.edu. 17 Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX, USA. sweaver@utmb.edu. 18 Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA. sweaver@utmb.edu. 19 Institute for Translational Sciences, University of Texas Medical Branch, Galveston, TX, USA. sweaver@utmb.edu. 20 Sealy Center for Structural Biology and Molecular Biophysics, University of Texas Medical Branch, Galveston, TX, USA. sweaver@utmb.edu. 21 Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA. peshi@utmb.edu. 22 Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA. peshi@utmb.edu. 23 Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX, USA. peshi@utmb.edu. 24 Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA. peshi@utmb.edu. 25 Institute for Translational Sciences, University of Texas Medical Branch, Galveston, TX, USA. peshi@utmb.edu. 26 Sealy Center for Structural Biology and Molecular Biophysics, University of Texas Medical Branch, Galveston, TX, USA. peshi@utmb.edu. # Contributed equally. PMID: 33106671 PMCID: PMC8158177 DOI: 10.1038/s41586-020-2895-3 Item in Clipboard Full text links Cite Display options Display options Format AbstractPubMedPMID Erratum in Author Correction: Spike mutation D614G alters SARS-CoV-2 fitness. Plante JA, Liu Y, Liu J, Xia H, Johnson BA, Lokugamage KG, Zhang X, Muruato AE, Zou J, Fontes-Garfias CR, Mirchandani D, Scharton D, Bilello JP, Ku Z, An Z, Kalveram B, Freiberg AN, Menachery VD, Xie X, Plante KS, Weaver SC, Shi PY. Plante JA, et al. Nature. 2021 Jul;595(7865):E1. doi: 10.1038/s41586-021-03657-2. Nature. 2021. PMID: 34131306 Free PMC article. No abstract available. Abstract The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein substitution D614G became dominant during the coronavirus disease 2019 (COVID-19) pandemic1,2. However, the effect of this variant on viral spread and vaccine efficacy remains to be defined. Here we engineered the spike D614G substitution in the USA-WA1/2020 SARS-CoV-2 strain, and found that it enhances viral replication in human lung epithelial cells and primary human airway tissues by increasing the infectivity and stability of virions. Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs, supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission. Sera from hamsters infected with D614 virus exhibit modestly higher neutralization titres against G614 virus than against D614 virus, suggesting that the mutation is unlikely to reduce the ability of vaccines in clinical trials to protect against COVID-19, and that therapeutic antibodies should be tested against the circulating G614 virus. Together with clinical findings, our work underscores the importance of this variant in viral spread and its implications for vaccine efficacy and antibody therapy. PubMed Disclaimer Conflict of interest statement Competing financial interests X.X., V.D.M., and P.-Y.S. have filed a patent on the reverse genetic system and reporter SARS-CoV-2. Other authors declare no competing interests. Figures Extended Data Figure 1.. Experimental design of… Extended Data Figure 1.. Experimental design of hamster infection and sample harvest. (a) Graphical overview… Extended Data Figure 1.. Experimental design of hamster infection and sample harvest. (a) Graphical overview of experiment to assess the impact of G614 mutation on replication in the respiratory system of hamsters. (b) Schematic organs harvested from hamsters sacrificed on days 2, 4, and 7 post-infection. Illustration of hamster lung adapted from Reznik, G. et al. Clinical anatomy of the European hamster. Cricetuscricetus, L., For sale by the Supt of Docs, U.S. Govt. Print. Off., 1978. Extended Data Figure 2.. Validation of competition… Extended Data Figure 2.. Validation of competition assay by Sanger sequencing. (a) The correlation between… Extended Data Figure 2.. Validation of competition assay by Sanger sequencing. (a) The correlation between input PFU ratios and output RT-PCR amplicon ratios determined by Sanger sequencing. D614 and G614 viruses were mixed at PFU ratios of 10:1, 5:1, 3:1, 1:1, 1:3, 1:5, or 1:10. Total RNA of the virus mixtures were extracted and amplified by RT-PCR. The D614/G614 ratios were calculated by the peak heights of Sanger sequencing. Data were analyzed by linear regression with correlation coefficients (r) and significance (p). Symbols represent individual replicates and the solid line represents the fitted line. Data is derived from a single experiment conducted in duplicate. (b) Assay range evaluation. The ratio of D614/G614virus mixture calculated from Sanger sequencing was consistent when using a wide range of virus amounts. The D614/G614 viruses were mixed at 1:1PFU ratio. The total titers of the mixed viruses were 102, 103, 104, 105, and 106 PFU. The total RNA of virus mixture was isolated and amplified by RT-PCR. The D614/G614 ratios were calculated by the peak heights from Sanger sequencing. Symbols represent individual replicates, bar heights represent the mean, and error bars represent the standard deviation. Data is derived from a single experiment conducted in triplicate. Extended Data Figure 3.. D614G substitution significantly… Extended Data Figure 3.. D614G substitution significantly enhances SARS-CoV-2 replication in primary human airway tissues… Extended Data Figure 3.. D614G substitution significantly enhances SARS-CoV-2 replication in primary human airway tissues from a different donor. D614 and G614 viruses were equally mixed and inoculated onto the airway tissue at a total MOI of 5. This airway tissue was produced from a different donor than that used in Figure 3. The tissues were washed by DPBS to collect the secreted viruses every day from days 1 to 5. The total RNAs were isolated and amplified by RT-PCR. The ratio of D614 and G614 viruses after competition were measure by Sanger sequencing. Circles represent individual samples (n=6, two independent experiments conducted in triplicate). The midline represents the sample mean, and the shaded region represents +/− one unit of standard error about the mean. The width of the catseye plot represents the distribution of the model-adjusted means, and the heights extend to span 99.8% of the distribution of the mean. The y-axis is displayed on the log10 scale such that the null value is 1. P values are calculated for the group (strain) coefficient for each linear regression model, and are reported for all instances of p<0.05. Extended Data Figure 4.. SARS-CoV-2 G614 is… Extended Data Figure 4.. SARS-CoV-2 G614 is more stable than D614. Equal amounts (10 5 … Extended Data Figure 4.. SARS-CoV-2 G614 is more stable than D614. Equal amounts (105 PFU/ml) of D614 and G614 viruses were incubated in DPBS at 42°C (a), at 37°C (b), or 33°C (c), respectively. At 0 h, 0.5 h, 1 h, 2 h, 4 h, and 8 h, the viruses were quantified for their infectious levels by plaque assay on Vero E6 cells. The detect limitation of plaque assay is 10 PFU/ml. The percentage of remaining infectious viruses were normalized by the average titers at 0 h. Symbols represent individual replicates, bar heights represent the mean, and error bars represent the standard deviation. P values were determined by two-tailed Mann-Whitney test (n=9, from three independent experiments, each conducted in triplicate), and results of p<0.05 are indicated. Extended Data Figure 5.. Scheme for preparing… Extended Data Figure 5.. Scheme for preparing the D614 SARS-CoV-2-infected hamster sera for neutralization assay. Extended Data Figure 5.. Scheme for preparing the D614 SARS-CoV-2-infected hamster sera for neutralization assay. Eight sera were collected: Four sera (number 1–4) collected on day 28 post infection and another four sera (number 5–8) collected on day 49 after the second viral infection. Extended Data Figure 6.. Construction of G614… Extended Data Figure 6.. Construction of G614 mNeonGreen SARS-CoV-2. (a) Diagram of the construction. The… Extended Data Figure 6.. Construction of G614 mNeonGreen SARS-CoV-2. (a) Diagram of the construction. The D614G mutation was introduced into a mNeonGreen reporter SARS-CoV-2 using the method as described previously. (b) Plaque morphologies of D614 and G614 mNeonGreen SARS-CoV-2. Extended Data Figure 7.. Neutralization activities of… Extended Data Figure 7.. Neutralization activities of hamster sera against D614 and G614 mNeonGreen SARS-CoV-2. Extended Data Figure 7.. Neutralization activities of hamster sera against D614 and G614 mNeonGreen SARS-CoV-2. (a) Neutralizing curves of eight hamster sera against D614 and G614 mNeonGreenSARS-CoV-2. The neutralizing curve for serum 5 is shown in Fig. 4c. Symbols represent individual samples and the solid line represents the fitted curve. Data is derived from a single experiment conducted in duplicate. (b) Calculated NT50 values and ratios of 1/NT50 for all eight hamster sera. The mean ratios were determined by (D614 1/NT50)/(G614 1/NT50). Extended Data Figure 8.. Neutralization activities of… Extended Data Figure 8.. Neutralization activities of human mAbs against D614 and G614 mNeonGreen SARS-CoV-2… Extended Data Figure 8.. Neutralization activities of human mAbs against D614 and G614 mNeonGreen SARS-CoV-2 in Experiment I. (a) Neutralizing curves of eleven mAbs against D614 and G614 reporter SARS-CoV-2. The neutralizing curve for mAb18 is shown in Fig. 4f. Symbols represent individual replicates and the solid line represents the fitted curve. Data is derived from a single experiment conducted in duplicate. (b) Calculated NT50 values for all eleven mAbs. Extended Data Figure 9.. Neutralization activities of… Extended Data Figure 9.. Neutralization activities of human mAbs against D614 and G614 mNeonGreen SARS-CoV-2… Extended Data Figure 9.. Neutralization activities of human mAbs against D614 and G614 mNeonGreen SARS-CoV-2 in Experiment II. (a) Neutralizing curves of eleven mAbs against D614 and G614 reporter SARS-CoV-2. Symbols represent individual replicates and the solid line represents the fitted curve. Data is derived from a single experiment conducted in either duplicate or quadruplicate. (b) Calculated NT50 values for all eleven mAbs. (c) Summary of NT50 ratios from two independent experiments. The ratios were determined by (D614 NT50)/(G614 NT50) Figure 1.. D614G substitution improves SARS-CoV-2 replication… Figure 1.. D614G substitution improves SARS-CoV-2 replication on Calu-3 cells through increased virion infectivity. (a) … Figure 1.. D614G substitution improves SARS-CoV-2 replication on Calu-3 cells through increased virion infectivity. (a) Construction of mutant G614 SARS-CoV-2. A single nucleotide A-to-G substitution was introduced to construct the spike D614G mutation in the infectious cDNA clone of SARS-CoV-2. (b) Plaque morphologies of D614 and G614 viruses, developed on day 2 pi in Vero E6 cells. (c-h) Viral replication and genomic RNA/PFU ratios of D614 and G614 viruses produced from Vero E6 cells (c-e) and from Calu-3 cells (f-h). Cells were infected at an MOI of 0.01. Infectious viral titers (c,f) and genomic RNA levels (d,g) in culture medium were determined by plaque assay and real-time RT-qPCR, respectively. The genomic RNA/PFU ratios (e,h) were calculated to indicate virion infectivity. Symbols represent individual samples, bar heights represent means, and error bars represent standard deviations. P values were determined by two-tailed Mann–Whitney test from a sample size of n=6 (two independent experiments, conducted in triplicate). All results of p<0.05 are reported. (i,j) Spike protein cleavage of purified virions. Purified D614 and G614 virions were analyzed by Western blot using polyclonal antibodies against spike and nucleocapsid. Full-length spike , S1/S2 cleavage form, and S2’ protein are annotated. Results from two independent experiments are presented for virions produced from Calu-3 cells (i) and Vero E6 cells (j). Figure 2.. D614G substitution increases SARS-CoV-2 replication… Figure 2.. D614G substitution increases SARS-CoV-2 replication in the upper airway, but not the lungs,… Figure 2.. D614G substitution increases SARS-CoV-2 replication in the upper airway, but not the lungs, of hamsters. (a-i) 3–4-Week-old male golden Syrian hamsters were infected intranasally with 2×104 PFU of D614 or G614 SARS-CoV-2, or PBS. All data are from a single experiment. (a) Weight loss was monitored for seven days pi. Symbols represent means, error bars represent standard deviation. Sample sizes were n=18 for infected cohorts and n=14 for the mock cohort at days 0–2, n=12 for infected cohorts and n=10 for the mock cohort at days 3–4, and n=6 for all cohorts at days 5–7. Weight loss was analyzed by two-factor ANOVA with Tukey’s post-hoc test, with p>0.05 at all timepoints. (b,c) Infectious titers and (d) viral genomes were measured in the nasal wash, trachea, and lung on days 2 (b,d), 4 (c,d), and 7 (d) pi. (e,f) Genome/PFU ratios on days 2 (e) and 4 (f) pi were calculated as a measure of infectivity. (b-f) Symbols represent individual animals (n=6). Midlines (b,c,e,f) and bar heights (d) represent means. (b-f) Error bars represent standard deviation. Two-factor ANOVA with Sidak’s post-hoc test are reported for p<0.05. (g-i) Hamsters were inoculated with 1:1 mixtures of D614 and G614 viruses (104 PFU each). Nasal wash, trachea, and lung were collected on days 2 (g), 4 (h), and 7 (i) pi. Relative fitness was assessed by Sanger sequencing. (g-i) Circles represent individual animals (n=6). Midline represents the mean. Shaded regions represent one unit of standard error about the mean. The width of the catseye plot represents the distribution of the model-adjusted means, and heights extend to 99.8% of the distribution. The y-axis is log10 scaled. P values are calculated for the group (strain) coefficient for each linear regression model, and are reported for p<0.05. Figure 3.. D614G substitution significantly enhances SARS-CoV-2… Figure 3.. D614G substitution significantly enhances SARS-CoV-2 replication in primary human airway tissues. (a) Experimental… Figure 3.. D614G substitution significantly enhances SARS-CoV-2 replication in primary human airway tissues. (a) Experimental scheme. D614 and G614 viruses were inoculated onto the primary human airway tissues at an MOI of 5. After incubation for 2 h, the culture was washed with DPBS, then maintained at for 5 days. To harvest, DPBS was added and allowed to incubate at 37°C for 30 min to elute the virus. (b-d) Viral replication and genomic RNA/PFU ratios. The amounts of infectious virus (b) and genomic RNA (c) were quantified by plaque assay and real-time RT-qPCR, respectively. The genomic RNA/PFU ratio (d) was calculated to indicate virion infectivity. Symbols represent individual samples, bar heights represent means, and error bars represent standard deviations. P values were determined by two-tailed Mann–Whitney test (n=6, two independent experiments conducted in triplicate). The results of the Mann-Whitney test are reported for all instances of p<0.05. (e,f) Competition assay. A mixture of D614 and G614 viruses with initial ratios of 1:1 (e), 3:1(f), or 9:1(g) were inoculated onto the human airway tissues at a total MOI of 5. Ratios after competition were measure by Sanger sequencing. Circles represent individual samples (n=6, two independent experiments conducted in triplicate). The midline represents the sample mean, and the shaded region represents +/− one unit of standard error about the mean. The width of the catseye plot represents the distribution of the model-adjusted means, and the heights extend to span 99.8% of the distribution of the mean. The y-axis is displayed on the log10 scale such that the null value is 1. P values are calculated for the group (strain) coefficient for each linear regression model, and are reported for all instances of p<0.05. Figure 4.. D614G substitution affects the neutralization… Figure 4.. D614G substitution affects the neutralization susceptibility of SARS-CoV-2. (a) Neutralizing activities of hamster… Figure 4.. D614G substitution affects the neutralization susceptibility of SARS-CoV-2. (a) Neutralizing activities of hamster sera against D614 and G614 mNeonGreen reporter SARS-CoV-2. Sera from D614 virus-infected hamsters (n=8) were tested for neutralizing titers against D614 and G614 reporter SARS-CoV-2, and the 1/NT50 values are plotted. Symbols represent sera from individual animals. (b) Ratio of 1/NT50 between D614 and G614 viruses. Symbols represent sera from individual animals (n=8), the midline represents the mean, and error bars represent standard deviation. (c) Representative neutralizing curve of hamster serum 5. Symbols represent individual replicates, the solid line represents the fitted curve, and the dotted line indicates 50% viral inhibition. (d) Neutralizing activities of eleven human mAbs against D614 and G614 mNeonGreen SARS-CoV-2. Symbols represent individual mAbs. The data represents one of the two independent experiments. (e) Ratio of NT50 between D614 and G614 viruses. The averages of the NT50 ratios from two independent experiments performed in duplicates are shown. Symbols represent individual mAbs, the midline represents the mean, and the error bars represent the standard deviation. (f) Representative neutralizing curve of mAb18. Symbols represent individual replicates, the solid line represents the fitted curve, and the dotted line indicates 50% viral inhibition. All figures (13) See this image and copyright information in PMC Update of Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibility. Plante JA, Liu Y, Liu J, Xia H, Johnson BA, Lokugamage KG, Zhang X, Muruato AE, Zou J, Fontes-Garfias CR, Mirchandani D, Scharton D, Bilello JP, Ku Z, An Z, Kalveram B, Freiberg AN, Menachery VD, Xie X, Plante KS, Weaver SC, Shi PY. Plante JA, et al. bioRxiv [Preprint]. 2020 Sep 2:2020.09.01.278689. doi: 10.1101/2020.09.01.278689. bioRxiv. 2020. Update in: Nature. 2021 Apr;592(7852):116-121. doi: 10.1038/s41586-020-2895-3. PMID: 32908978 Free PMC article. Updated. Preprint. Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibility. Shi PY, Plante J, Liu Y, Liu J, Xia H, Johnson B, Lokugamage K, Zhang X, Muruato A, Zou J, Fontes-Garfias C, Mirchandani D, Scharton D, Kalveram B, Bilello J, Ku Z, An Z, Freiberg A, Menachery V, Xie X, Plante K, Weaver S. Shi PY, et al. Res Sq [Preprint]. 2020 Sep 10:rs.3.rs-70482. doi: 10.21203/rs.3.rs-70482/v1. Res Sq. 2020. Update in: Nature. 2021 Apr;592(7852):116-121. doi: 10.1038/s41586-020-2895-3. PMID: 32935091 Free PMC article. Updated. Preprint. Comment in Emergence of a Highly Fit SARS-CoV-2 Variant. Baric RS. Baric RS. N Engl J Med. 2020 Dec 31;383(27):2684-2686. doi: 10.1056/NEJMcibr2032888. Epub 2020 Dec 16. N Engl J Med. 2020. PMID: 33326716 No abstract available. D614G and SARS-CoV-2 replication fitness. Engelman KD, Engelman AN. Engelman KD, et al. Signal Transduct Target Ther. 2021 Mar 1;6(1):99. doi: 10.1038/s41392-021-00498-3. Signal Transduct Target Ther. 2021. PMID: 33649290 Free PMC article. No abstract available. References Korber B et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell, 10.1016/j.cell.2020.06.043 (2020). - DOI - PMC - PubMed Yurkovetskiy L et al. Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant. BioRxiv (2020). - PMC - PubMed Zhou P et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273, 10.1038/s41586-020-2012-7 (2020). - DOI - PMC - PubMed Domingo P et al. The four horsemen of a viral Apocalypse: The pathogenesis of SARS-CoV-2 infection (COVID-19). EBioMedicine 58, 102887, 10.1016/j.ebiom.2020.102887 (2020). - DOI - PMC - PubMed Smith EC, Blanc H, Surdel MC, Vignuzzi M & Denison MR Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics. PLoS Pathog 9, e1003565, 10.1371/journal.ppat.1003565 (2013). - DOI - PMC - PubMed Show all 30 references References Specific to the Methods Section Carr IM et al. Inferring relative proportions of DNA variants from sequencing electropherograms. Bioinformatics 25, 3244–3250, 10.1093/bioinformatics/btp583 (2009). - DOI - PubMed Johnson BA et al. Furin Cleavage Site Is Key to SARS-CoV-2 Pathogenesis. bioRxiv, 10.1101/2020.1108.1126.268854 (2020). - DOI Cumming G The New Statistics: Why and How. Psychol. Sci, 7–29, 10.1177/0956797613504966 (2014). - DOI - PubMed Andersen C Catseyes: Create Catseye Plots Illustrating the Normal Distribution of the Means. R package version 0.2.3 (2019). Publication types Research Support, N.I.H., Extramural Actions Search in PubMed Search in MeSH Add to Search Research Support, Non-U.S. Gov't Actions Search in PubMed Search in MeSH Add to Search MeSH terms Animals Actions Search in PubMed Search in MeSH Add to Search Antibodies, Neutralizing / immunology Actions Search in PubMed Search in MeSH Add to Search Antibodies, Neutralizing / therapeutic use Actions Search in PubMed Search in MeSH Add to Search COVID-19 / immunology Actions Search in PubMed Search in MeSH Add to Search COVID-19 / transmission* Actions Search in PubMed Search in MeSH Add to Search COVID-19 / virology* Actions Search in PubMed Search in MeSH Add to Search COVID-19 Vaccines / immunology Actions Search in PubMed Search in MeSH Add to Search Cricetinae Actions Search in PubMed Search in MeSH Add to Search Disease Models, Animal Actions Search in PubMed Search in MeSH Add to Search Genetic Fitness* Actions Search in PubMed Search in MeSH Add to Search Humans Actions Search in PubMed Search in MeSH Add to Search Lung / virology Actions Search in PubMed Search in MeSH Add to Search Male Actions Search in PubMed Search in MeSH Add to Search Mesocricetus / virology Actions Search in PubMed Search in MeSH Add to Search Models, Biological Actions Search in PubMed Search in MeSH Add to Search Mutation* Actions Search in PubMed Search in MeSH Add to Search Nasal Mucosa / virology Actions Search in PubMed Search in MeSH Add to Search Neutralization Tests Actions Search in PubMed Search in MeSH Add to Search Protein Stability Actions Search in PubMed Search in MeSH Add to Search SARS-CoV-2 / genetics* Actions Search in PubMed Search in MeSH Add to Search SARS-CoV-2 / immunology Actions Search in PubMed Search in MeSH Add to Search SARS-CoV-2 / pathogenicity Actions Search in PubMed Search in MeSH Add to Search SARS-CoV-2 / physiology* Actions Search in PubMed Search in MeSH Add to Search Spike Glycoprotein, Coronavirus / genetics* Actions Search in PubMed Search in MeSH Add to Search Tissue Culture Techniques Actions Search in PubMed Search in MeSH Add to Search Trachea / virology Actions Search in PubMed Search in MeSH Add to Search Viral Load Actions Search in PubMed Search in MeSH Add to Search Virion / chemistry Actions Search in PubMed Search in MeSH Add to Search Virion / pathogenicity Actions Search in PubMed Search in MeSH Add to Search Virion / physiology Actions Search in PubMed Search in MeSH Add to Search Virus Replication / genetics Actions Search in PubMed Search in MeSH Add to Search Substances Antibodies, Neutralizing Actions Search in PubMed Search in MeSH Add to Search COVID-19 Vaccines Actions Search in PubMed Search in MeSH Add to Search Spike Glycoprotein, Coronavirus Actions Search in PubMed Search in MeSH Add to Search spike protein, SARS-CoV-2 Actions Search in PubMed Search in MeSH Add to Search Grants and funding R21 AI145400/AI/NIAID NIH HHS/United States R01 AI134907/AI/NIAID NIH HHS/United States R00 AG049092/AG/NIA NIH HHS/United States UC7 AI094660/AI/NIAID NIH HHS/United States R01 AI153602/AI/NIAID NIH HHS/United States TL1 TR001440/TR/NCATS NIH HHS/United States R43 AI145617/AI/NIAID NIH HHS/United States UL1 TR001439/TR/NCATS NIH HHS/United States U01 AI151801/AI/NIAID NIH HHS/United States U19 AI142759/AI/NIAID NIH HHS/United States R24 AI120942/AI/NIAID NIH HHS/United States Show all 11 grants LinkOut - more resources Full Text Sources Europe PMC Nature Publishing Group PubMed Central Other Literature Sources H1 Connect - Access expert opinions and insights on biomedical research. The Lens - Patent Citations Database Medical MedlinePlus Health Information Molecular Biology Databases GlyGen glycoinformatics resource Miscellaneous NCI CPTAC Assay Portal Full text links [x] Nature Publishing Group Free PMC article [x] Cite Copy Download .nbib .nbib Format: AMA APA MLA NLM Send To Clipboard Email Save My Bibliography Collections Citation Manager [x] NCBI Literature Resources MeSH PMC Bookshelf Disclaimer The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited. Follow NCBI Twitter Facebook LinkedIn GitHub Connect with NLM Twitter SM-Facebook SM-Youtube National Library of Medicine 8600 Rockville Pike Bethesda, MD 20894 Web Policies FOIA HHS Vulnerability Disclosure Help Accessibility Careers NLM NIH HHS USA.gov